+639667705788

0 items ₱ 0.00

+639667705788

Abiraterone Acetate

Showing all 3 results

Show sidebar

Sold out

Abirakast Abiraterone Acetate 250 mg Tablet

Abirakast 250 mg Tablet

Molecule : Abiraterone AcetateManufacturer : Aprazer Healthcare

Oncology, Prostate Cancer

Abirapro 250 mg Tablet

Molecule : Abiraterone AcetateManufacturer : Glenmark

Oncology, Prostate Cancer

Sold out

Abiraxen 250 mg Tablet

Molecule : Abiraterone AcetateManufacturer : Everest Pharma

Oncology, Prostate Cancer

EU Approves First-Line Targeted Treatment for BRAF-Mutant Advanced Colon Cancer

The EC has now given its green light to encorafenib (Braftovi) when used in combination with cetuximab (Erbitux) and FOLFOX

June 27, 2026

Iressa (Gefitinib): Still a Reliable First-Line Option for Lung Cancer

In the past, a lung cancer diagnosis usually meant that aggressive chemotherapy had to begin immediately. Though chemotherapy still plays

June 18, 2026

Keytruda vs. Opdivo: Which Immunotherapy is Right for You?

Treatment for advanced cancer has come a long way from what was available in the past. For many years now,

June 15, 2026

Start typing to see posts you are looking for.

Name

DOB (Age)

Gender

Phone number

Email Id

Country/Location

Primary Diagnosis

Date of Diagnosis

Current Symptoms

Previous Medical Conditions

Allergies

Current Treatment Plan

Previous Treatments Received

Medications

Surgeries (if any)

Radiation therapy (details)

Response to Treatments

Current Medications and Supplements

Attach Reports (if available)

Pathology Reports

Imaging Reports (CT, MRI, PET scans, etc.)

Blood Tests (e.g., tumor markers, CBC, liver/kidney function tests)

Genetic Testing (if any, e.g., EGFR, HER2, BRCA mutations)

Recent Imaging Date and Findings

What specific areas do you need a second opinion on?

Are you seeking recommendations for alternative treatments?

Abiraterone Acetate

Related Posts:

EU Approves First-Line Targeted Treatment for BRAF-Mutant Advanced Colon Cancer

Iressa (Gefitinib): Still a Reliable First-Line Option for Lung Cancer

Keytruda vs. Opdivo: Which Immunotherapy is Right for You?